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Background: Human replication factor C4 (RFC4) is involved in DNA replication as a clamp loader and is aberrantly
regulated across a range of cancers. The current study aimed to investigate the function of RFC4 in colorectal
cancer (CRC).
Methods: The mRNA levels of RFC4 were assessed in 30 paired primary CRC tissues and matched normal colonic
tissues by quantitative PCR. The protein expression levels of RFC4 were evaluated by western blotting (n = 16) and
immunohistochemistry (IHC; n = 49), respectively. Clinicopathological features and survival data were correlated
with the expression of RFC4 by IHC analysis in a tissue microarray comprising 331 surgically resected CRC. The
impact of RFC4 on cell proliferation and the cell cycle was assessed using CRC cell lines.
Results: RFC4 expression was significantly increased in CRC specimens as compared to adjacent normal colonic
tissues (P <0.05). High levels of RFC4, determined on a tissue microarray, were significantly associated with
differentiation, an advanced stage by the Tumor-Node-Metastasis (TNM) staging system, and a poor prognosis,
as compared to low levels of expression (P <0.05). However, in multivariate analysis, RFC4 was not an independent
predictor of poor survival for CRC. In vitro studies, the loss of RFC4 suppressed CRC cell proliferation and induced
S-phase cell cycle arrest.
Conclusion: RFC4 is frequently overexpressed in CRC, and is associated with tumor progression and worse survival
outcome. This might be attributed to the regulation of CRC cell proliferation and cell cycle arrest by RFC4.
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Colorectal cancer (CRC) is one of the leading causes of
cancer-related deaths worldwide. CRC arises through the
accumulation of genetic mutations and epigenetic alter-
ations that result in the transformation of normal colon
epithelial cells into adenomas, which may be the precur-
sor of CRC, and ultimate into cancers. Alongside the* Correspondence: pengjunsheng@tom.com; wangjply@yahoo.com
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numerous molecular alterations have been identified
[1,2]. Understanding the underlying molecular mecha-
nisms of CRC might help guide clinical therapies. For
example, current clinical guidelines recommend check-
ing the KRAS mutation status before treating CRC pa-
tients with EGFR inhibitors.
Human replication factor C (RFC) is a multimeric pro-
tein consisting of five distinct subunits that are highly
conserved through evolution [3]. The RFC family func-
tions as clamp loaders that load PCNA onto DNA in an
ATP-dependent process during DNA synthesis [4-7]. In
addition, RFCs play an important role in DNA repair ac-
tivities following DNA damage [8,9]. Among the RFCs,
the RFC4 gene, that encodes the fourth largest subunittd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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array or meta-analysis to be deregulated in diverse malig-
nancies, including prostate cancer, cervical cancer, and
head and neck squamous cell carcinomas [10-13]. How-
ever, the role of RFCs in cancer initiation and progression
remains unclear. In the current study, we investigated the
expression levels of RFC4 in CRCs, and determined the
potential biological function of RFC4 in CRC.
Materials and methods
Data mining
The expression of RFC4 mRNA in CRC tissues was
obtained by The Cancer Genome Atlas (TCGA), Gene
Expression Omnibus databases (GEO) and BioGPS data-
base (Biogps.org). For TCGA analysis, we queried The
Cancer Genome Atlas [http://tcga-data.nci.nih.gov/] for
colon cancer patients. “Level 3 of Exp-Gene” files from
COAD Data Matrix Datasets were downloaded and
used to extract mRNA expression for RFC4. For GEO
data analysis, we downloaded and analyzed data publicly
available from the GEO [http://www.ncbi.nlm.nih.gov/
geo/; 82 samples from GSE9348 and 105 samples from
GSE5206 and 64 samples from GSE8671]. “Series Matrix”
Files were used to extract mRNA expression for RFC4. The
genes amplification folds were analyzed and visualized by
Graph Prism6 (GraphPad software Inc., San Diego, CA).
Patients and tissue specimens
First, to detect the expression dynamics of RFC4 in
CRC, 30 paired freshly frozen specimens and 49 paired
formalin-fixed, paraffin-embedded (FFPE) specimens
from primary CRC tissues and patient-matched normal
colonic tissues were obtained from the 6th Affiliated
Hospital of Sun Yat-sen University (Guangzhou, China).
Each normal colonic tissue was acquired from a distance
of at least 10 cm from the tumor margin. Second, to de-
termine the clinical relevance of RFC4 in CRC, 331 FFPE
CRC tumor specimens resected between January 2000
and December 2006 were obtained from the path-
ology archives at the 1st Affiliated Hospital of Sun Yat-sen
University (Guangzhou, China) for tissue microarray ana-
lyses. Among the 331 patients, 91 patients (27.5%) had
been censored as death and 97 patients (29.3%) had devel-
oped distant metastasis or local recurrence after a median
follow-up of 73.0 months (range 1–122). None of the
patients had received neoadjuvant chemotherapy or radio-
therapy, and the status of all samples was confirmed by
pathologists after resection. Tumor tissues were staged ac-
cording to the 7th edition of the Union for International
Cancer Control Tumor-Node-Metastasis (TNM) staging
system. Written informed consents for using tissue sam-
ples for research purposes were obtained from all patients.
This study was approved by the Institutional Review
Board of the 1st and 6th Affiliated Hospital of Sun Yat-SenUniversity and all clinical and pathological data of the
enrolled patients were collected from the Institutional
Review Board approved CRC database, which was main-
tained by specialists.
Cell lines
The human CRC cell lines, SW480 and DLD1, were ob-
tained from the Culture Collection of the Chinese Academy
of Science (Shanghai, China) and cultured in RPMI 1640
media. All media were supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, and 100 μg/ml streptomycin.
The cells were cultured at 37°C in a humidified atmosphere
of 95% air and 5% CO2.
RNA extraction and quantitative PCR
All RNA extractions were performed using the Trizol
Reagent (Life Technologies, Carlsbad, CA, USA) according
to the manufacturer’s protocols. For first-strand comple-
mentary DNA synthesis, total RNA was reverse-transcribed
with an oligo-dT primer using the RevertAid™ First Strand
cDNA Synthesis Kit (Fermentas, Burlington, Canada).
Quantitative PCR (qPCR) reactions were performed with
an ABI PRISM® 7500 Fast Real-time PCR System (Applied
Biosystems, Foster City, CA, USA) and a SYBR Green
qPCR Mix Kit (Takara, Japan). β-actin expression was used
as the normalization control. The following temperature
profiles were used: initial heating at 95°C for 10 min,
followed by 40 cycles of denaturation at 95°C for 15 s,
annealing at 60°C for 60 s, and extension at 95°C for 15 s.







Data were analyzed using the 2-ΔΔCt method.
Western blotting
Total cellular proteins were extracted from tissues or
cells, separated by SDS-PAGE, and transferred onto a poly-
vinylidene difluoride membrane (Pall, New York, USA).
Membranes were blocked with 5% nonfat milk in 1%
Tween-PBS (PBST) and then probed overnight with anti-
RFC4 rabbit polyclonal antibody (1:1000, Epitomics,
Burlingame, CA, USA) or anti-ACTB antibody (1:1000,
Proteintech, Chicago, IL, USA). After three washing
steps of 10 min in PBST, membranes were incubated
with species-appropriate fluorescently-conjugated sec-
ondary antibodies (1:10000 in PBST, LI-COR Biosciences,
Lincoln, NE, USA) for 1 h at room temperature. The im-
munoreactive signals were detected using the two-color
fluorescent western blotting Odyssey infrared imaging sys-
tem (LI-COR Biosciences).
Figure 1 RFC4 is overexpressed in CRC tissues. (A) RFC4 mRNA levels were assessed from The Cancer Genome Atlas (TCGA) and the
Gene Expression Omnibus databases (GEO, GSE9348, GSE5206 and GSE8671). Bounds of the boxes denote interquartile range; solid lines
denote median, whiskers denote 95% and 5% confidence limits, respectively. (B) Expression of RFC4 mRNA in 30 paired CRC tumor and
adjacent non-tumor tissues. Each bar is the log2 value of the ratio of RFC4 expression levels between CRC (T) and matched normal tissues
(N) from the same patient. Red bars (bar value ≥1) indicate high RFC4 mRNA levels. Blue and green bars represent low and normal
expression of RFC4 mRNA, respectively. Each sample was analyzed twice. (C) Western blots for RFC4 in matched-pairs of CRC tumor and
non-tumor tissues. High RFC4 protein expression in CRC is seen in 12 of 16 patients. (D) Distribution of RFC4 immunoreactivity scores in
tumor and paired-non-tumor tissues from the tissue microarray. CRC tissues exhibite higher RFC4 expression than normal colonic tissues.
(E) ROC curves analysis to determine the cutoff score for the high expression of RFC4. The area under curve (AUC) is 0.741, and the
cutoff point of RFC4 for overexpression is 4.5.
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To validate the overexpression of RFC4 and to define
the clinical roles of RFC4 in CRC, two TMAs were con-
structed. The first contained tissue cores of 49 pairedspecimens of primary CRC tissues and matched normal
colonic tissues. The second contained additional spots of
331 resected CRC specimens. For each case, two cores
(1 mm diameter) were taken from the selected tumor
Table 2 Association of RFC4 protein expression with
clinicopathologic characteristics in CRC





Female 147 59 (40.1%) 88 (59.9%)
Male 184 93 (45.9%) 91 (54.1%)
Age 0.301
≤60 167 72 (43.1%) 95 (56.9%)
>60 164 80 (48.8%) 84 (51.2%)
Tumor location 0.344
Colon 154 75 (48.7%) 79 (51.3%)
Rectal 177 77 (43.5%) 100 (56.5%)
Differentiation 0.004
Well/Moderate 299 145 (48.5%) 154 (51.5%)
Poorly 32 7 (21.9%) 25 (78.1%)
Preoperative 0.656
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taken from histologically confirmed normal adjacent
colorectal mucosa to construct the TMAs using Tissue
Array (Alphelys, MINIPORE, Plaisir, France). The TMAs
were performed as we described previously [14].
Immunohistochemistry (IHC) staining
The TMAs were deparaffinized in xylene and rehy-
drated with graded ethanol. Sections were then heated
in antigen retrieval solution (EDTA, pH 9.0) for
20 min and incubated with 3% H2O2 for 10 min. The
sections were then incubated with anti-RFC4 rabbit
polyclonal antibody (1:800, Epitomics) at 4°C overnight.
The sections were then treated with the secondary
antibody for 15 min at room temperature and stained
with 3, 3′-diaminobenzidine until brown granules
appeared in the membrane, cytoplasm, or nucleus (Dako,
EnvisionSystem/DAB-chromogen, Glostrup, Denmark).
The sections were counterstained with hematoxylin
for 2 min at room temperature. A negative control was
employed by exchanging the specific primary antibody
with non-immune serum immunoglobulins at a 1:200
dilution.
Evaluation of IHC staining and selection of the optimal
cutoff score
The immunoreaction was semi-quantitatively scored by
assessing the extent and intensity of nuclear staining.Table 1 Clinical characteristics of the patients included in
analyses of RFC4 expression evaluated by qPCR, Western
and IHC
Characteristics qPCR cases
(n = 30 pairs)
Western cases
(n = 16 pairs)
IHC cases
(n = 49 pairs)
Age (years) Mean ±
SD
57.8 ± 10.9 56.8 ± 11.2 64.0 ± 12.3
Sex
Female 6 (20.0%) 5 (31.2%) 16 (32.7%)
Male 24 (80.0%) 11 (68.8%) 33 (67.3%)
Tumor location
Colon 16 (53.3%) 9 (56.3%) 23 (46.9%)
Rectal 14 (46.7%) 7 (43.7%) 26 (53.1%)
Differentiation
Well 5 (16.7%) 2 (12.5%) 6 (12.2%)
Moderate 21 (70.0%) 12 (75.0%) 37 (75.6%)
Poorly 4 (13.3%) 2 (12.5%) 6 (12.2%)
TNM stage
I 3 (10.0%) 2 (12.5%) 6 (12.2%)
II 19 (63.3%) 9 (56.3%) 18 (36.8%)
III 8 (26.7%) 5 (31.2%) 22 (44.9%)
IV 0 (0%) 0 (0%) 3 (6.1%)Weak cytoplasmic staining was identified in some cases.
The intensity of nuclear staining was scored as follows:
negative (0), weak (1), moderate (2), and strong (3). The
extent of nuclear staining was graded into quartiles
according to the percentage of stained cells in each field:
0-25% (1), 26-50% (2), 51-75% (3) and 76-100% (4). The
merged overall score (staining intensity plus stainingCEA level
< 5 ng/ml 194 89 (45.9%) 105 (54.1%)




< 37 U/ml 238 109 (45.8%) 129 (54.2%)
≥37 U/ml 67 28 (41.8%) 39 (58.2%)
pT (invasion depth) 0.479
T1 6 1 (16.7%) 5 (83.3%)
T2 54 27 (50.0%) 27 (50.0%)
T3 233 106 (45.5%) 127 (54.5%)




N0 197 99 (49.2%) 98 (50.8%)




M0 299 138 (46.2%) 161 (53.8%)
M1 32 14 (43.8%) 18 (56.2%)
TNM stage 0.036
I + II 193 98 (50.8%) 95 (49.2%)
III + IV 138 54 (39.1%) 84 (60.9%)
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dependently by two blinded pathologists to the clinical
data (Huang and Fan).
To generate a logical cutoff score for further analysis,
the nuclear RFC4 expression scores of 49 paired CRC and
matched normal colonic tissues were subjected to the
receiver operating characteristic curve (ROC) analysis.
The score localized closest to the point at both max-
imum sensitivity and specificity (0.0, 1.0) was selected
as the cutoff score leading to the greatest number of
specimens which were correctly classified as tumor or
normal.Figure 2 Expression pattern of RFC4 in CRC by immunohistochemistr
full tissue spot (×100), while the high power photomicrographs (right side) sh
RFC4 expression positive. (A) negative nuclear staining; (B) weak nuclear stainRFC4 siRNA gene knockdown
To knockdown endogenous RFC4 expression, cell lines
were transfected with 20 nM of duplexed siRNA (RiboBio,
Guangzhou, China) using Lipofectamine® RNAiMAX
Reagent (Life Technologies). Duplex siRNAs included the
following: RFC4 siRNA #1 (sense 5′-CAACUCAGCUC
GUCAAUCAdTdT-3, antisense 3′-dTdTGUUGAGUCG
AGCAGUUAGU-5); RFC4 siRNA #2 (sense 5′-GACC
AAGGAUCGAGGAGUAdTdT-3, antisense 3′-dTdTCU
GGUUCCUAGCUCCUCAU-5); RFC4 siRNA #3 (sense
5′-GAAAGUGAUUACAGACAUUdTdT-3, antisense 3′-
dTdTCUUUCACUAAUGUCUGUAA-5). Duplexes ofy. The low power photomicrographs (left side) in each section show the
ow details of RFC4 expression (×400). Nuclear staining is considered
ing; (C) moderate nuclear staining; (D) strong nuclear staining.
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bled siRNA. SW480 and DLD1 cells were transfected with
RFC4 siRNA or scrambled siRNA according to the manu-
facturer’s instructions.Cell proliferation assays
Cells were plated at equal densities in 96-well plates for
24 h and then transiently transfected with the indicated
siRNAs (6 biological replicates per condition). Cell pro-
liferation was assessed using the Vybrant MTT Cell
Proliferation Assay Kit (Invitrogen) according to the
manufacturer’s instructions. Absorbance was measured
at 490 nm.
The effect of RFC4 on proliferation was also tested by
the 5-ethynyl-2′-deoxyuridine (EdU) cell proliferation
assay using the Cell-Light™ EdU DNA Cell Proliferation
Kit (RiboBio, Guangzhou, China). Briefly, cells (1 × 104)
were seeded in each well of 96-well plates for transfec-
tion with RFC4 siRNA or scrambled siRNA. After incu-
bation at 37°C under 5% CO2 for 96 h, 50 μM EdU was
added and the cells were incubated for another 2 h. Cells
were then fixed with 4% paraformaldehyde and stained
with Apollo® Dye Solution for proliferating cells. Nucleic
acids in all cells were stained with Hoechst 33342. The
extent of cell proliferation was calculated according to
the manufacturer’s instructions. Images were taken using
a fluorescence microscope (Olympus FSX100). All ex-
periments were performed in triplicate.Cell cycle analysis
Cells were trypsinized, washed with cold PBS, and fixed
overnight in 70% ethanol pre-chilled to −20°C. For the
measurement of DNA content, cells were stained with a
propidium iodide solution (50 mg/mL propidium iodide,
100 mg/mL RNase A, 0.05% Triton X-100 in PBS) and
incubated at 37°C in the dark for 30 min. DNA content
was assessed using a BD FACSCanto II flow cytometer
(BD Biosciences) with ModFit LT software (Verity Software
House, Topsham, ME).Figure 3 The prognostic value of RFC4 in CRC. Kaplan-Meier analysis of
in all 331 patients. High expressing patients (n = 179) are significantly less like
P values were determined by the log-rank test.Statistical analyses
Overall survival (OS) time was measured from the date
of surgery to the date of death due to any cause, or the
date of the last clinical follow-up. Disease-free survival
(DFS) time was defined as the time from surgery to the
date confirmed local failure, distant metastases, or death
due to disease or treatment, whichever occurred first.
Kaplan-Meier survival curves were evaluated by the
log-rank test. Univariate Cox regression analyses were
performed to determine the prognostic significance of
individual clinicopathologic variables. Multivariate analysis
to test statistical independence and the significance of
multiple predictors was performed by stepwise Cox ana-
lysis with backward selection using the Akaike Informa-
tion Criterion. Wilcoxon matched-pairs, signed-rank test
were used to assess IHC score within groups (cancer and
matched normal tissues). Chi-square tests were used
to compare dichotomized RFC4 groups and baseline
clinicopathologic factors. Mann–Whitney U test were
used to compare continuous variables and categorical var-
iables. The level of significance for all tests was defined as
P <0.05. All statistics were performed using SPSS v. 17.0
(SPSS, Inc., Chicago, IL).
Results
RFC4 is overexpressed in CRC
First, we analyzed the data from the TCGA and GEO for
mRNA expression in CRC patients. RFC4 expression was
higher in colon cancer than normal colon tissue (Figure 1A).
Furthermore, by using the BioGPS Gene Expression Atlas,
we found that RFC4 expression was highly expressed in
colon cancer (Additional file 1: Figure S1).
To validate our finding, RNA was extracted from 30
paired CRC and adjacent normal tissues, and qPCR was
done to measure the levels of RFC4 mRNA. RFC4 mRNA
was significantly elevated in 21 of 30 CRC tissues, com-
pared with patient-matched normal tissues (Figure 1B).
Western blot analysis also revealed overexpression of RFC4
in 12 of 16 cancer tissues that had analyzed by qPCR, com-
pared with normal colonic tissues (Figure 1C). Immunohis-
tochemistry on TMA contained an independent set of 49overall survival and disease- free survival was based on RFC4 expression
ly to survive compared with normal expressing patients (n = 152).
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tend to exhibit a higher level of RFC4 expression than
normal colonic tissue (P <0.05) (Figure 1D). The clinical
features of these patients were summarized in Table 1. To-
gether, these data confirm the up-regulation of RFC4 in
CRC.
For further survival analysis, ROC curve analysis of 49
paired specimens was performed to determine a reason-
able cutoff point for RFC4 overexpression (Figure 1E). A
score of 4.5, which maximizes the sum of sensitivity andTable 3 Univariate and multivariate analysis for overall surviv
Variable Univariate analysis











Well + Moderate 1
Poorly 2.736 (1.593-4.699)
Preoperative CEA level
< 5 ng/ml 1
≥ 5 ng/ml 2.480 (1.590-3.866)
Preoperative CA19-9 level
< 37 U/ml 1
≥37 U/ml 2.553 (1.614-4.038)
pT
T1 + T2 1








I + II 1
III + IV 2.460 (1.618-3.741)
RFC4 expression
Normal 1
High 1.745 (1.136-2.680)specificity according to the ROC curves, was determined
as the cutoff point.
RFC4 expression correlates with a poor prognosis in CRC
The potential significance of RFC4 protein levels in CRC
was examined by IHC on the TMA consisting of tissues
from 331 CRC tumors, which were divided into a normal
expression group and an overexpression group based
on the above cutoff value. Dichotomized groups were
evaluated in relation to clinicopathologic factors andal in CRC tissue microarray
Multivariate analysis
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summarized in Table 2 and Figure 2. RFC4 expression
positively correlated with differentiation and TNM stage
(P <0.05; Table 2). Patients with poorly differentiated or
advanced TNM stage CRC were frequently identified
with RFC4 overexpression. No significant associationsFigure 4 Proliferation of CRC cells after transfection with RFC4-siRNA
SW480 cells following transfection with scrambled siRNA (Sc), RFC4-siRNA#
transfection with scrambled siRNA (Sc), RFC4-siRNA#1, −siRNA#2 or -siRNA#3.
respectively. (E) Cell growth in control and SW480 cells transfected with scram
control and DLD1 cells transfected with scrambled or RFC4-siRNA#1 as ass
cell proliferation in SW480 and DLD1 cells. (G) EdU incorporation assay
or RFC4-siRNA. There is a significant reduction in the proliferation of Dwere noted between RFC4 expression and other clinico-
pathologic variables. In relation to clinical outcomes, high
levels of RFC4 expression were significantly associ-
ated with poor OS and DFS by Kaplan-Meier analysis
(Figure 3). The 5-year OS and 5-year DFS were 81%
and 78%, respectively for normal RFC4 expressionassessed by the MTT and EdU assays. (A) RFC4 expression in
1, −siRNA#2 or -siRNA#3. (B) RFC4 expression in DLD1 cells following
(C) and (D) Western blots paralleling the treatments in panels A and B,
bled or RFC4-siRNA#2 as assessed by the MTT assay. (F) Cell growth in
essed by the MTT assay. Transfection with RFC4 siRNA decreases
s for DNA synthesis in DLD1 cells transfected with scrambled siRNA
LD1 cells transfected with RFC-siRNA. *P <0.05.
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5-year OS and 5-year DFS of 67% and 65%, respectively.
In addition, univariate analysis revealed that the extent of
differentiation, CEA level, CA19-9 level, pN stage, pM
stage, and RFC4 expression were risk factors for
death in CRC. Further Multivariate analysis was per-
formed using the Cox proportional hazards model for
all of the significant variables in the univariate ana-
lysis, including differentiation, preoperative CEA level,
preoperative CA19-9 level, TNM stage and RFC4
expression Table 3. The results showed that RFC4
expression was not an independent predictor of worse
overall survival, which might attribute to that there
were more stage III/IV patients (60.9%) having high
expression levels of RFC4.
Down-regulation of RFC4 inhibits DNA synthesis and
proliferation of CRC cells
Each of three distinct RFC4 siRNAs sharply reduced
the expression of RFC4 mRNA and protein by 70%
to 85% in both SW480 and DLD1 cells (Figure 4A,
B, C and D). The number of viable SW480 and
DLD1 cells 120 h after RFC4-siRNA transfection was
significantly reduced (as assessed by the MTT assay)
compared to that of the scrambled siRNA or non-siRNA
groups (P <0.05) (Figure 4E and F). DNA synthesis in
RFC4 knockdown tumor cells was significantly inhibited
as compared to that in control tumor cells (P <0.05)
(Figure 4G).Figure 5 Effect of RFC4-siRNA transfection on the cell cycle of SW480
cytometry 48 h after transfection of scrambled siRNA or RFC4-siRNA in SW4
G0/G1 phase, S-phase, and G2/M phase following transfection with scrambDown-regulation of RFC4 induces S-phase arrest in CRC
cells
To determine whether the inhibition of tumor cell growth
was related to cell cycle regulation, the effects of RFC4
knockdown on cell cycle progression was investigated.
Notably, the percentages of both SW480 and DLD1 cells
in the S phase of the cell cycle were substantially increased
following RFC4 knockdown (Figure 5). These data indi-
cate that depletion of RFC4 induces S-phase cell cycle
arrest, which might contribute to the suppression of cell
proliferation.
Discussion
RFC family members play important roles in eukaryotic
DNA replication and the repair of DNA damage. Members
of the RFC family may also be involved in several other
biological processes such as S-phase checkpoint regulation,
sister chromatid cohesion and genome maintenance
[8,15,16]. Because cancer cells are actively replicating,
RFCs are presumably deregulated in cancer. Indeed,
this was evidenced by previous studies demonstrating
that high expression of RFC family members occurs
in diverse types of cancer. For example, amplification of
RFC3 is frequently found in esophageal adenocarcinoma
[17], while RFC2 is overexpressed in nasopharyngeal
carcinoma [18].
The current study showed that RFC4 is overexpressed
in CRC and that increased RFC4 expression is significantly
associated with poorly differentiated and advanced tumorand DLD1 cells. Cell cycle distribution was analyzed by flow
80 (A) and DLD1 (B) cells. The respective proportion of cells in the
led siRNA or RFC4-siRNA in SW480 (C) and DLD1 (D) cells. *P <0.05
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an unfavorable outcome in CRC patients. These findings
demonstrate that RFC4 may play an oncogenic role in
CRC. The vast majority of published studies on the RFC
family have focused on their biological functions. How-
ever, the role of RFCs in the development and progression
of cancer remains unclear. Thus, we further investigated
the relationship between RFC4 and the proliferation of
cancer cells. The knockdown of RFC4 expression in
CRC cell lines by siRNA resulted in a significant
decrease in cell proliferation assessed by both the MTT
and Edu assays. This result further supported our
contention that RFC4 is involved in DNA replication
in cancer cells.
Our data showed that knockdown of RFC4 by siRNA
significantly increases the number of CRC cells in the
S-phase. This finding is consistent with the effect of RFC4
in hepatocellular carcinoma and breast cancer [10,19] and
indicates that RFC4 acts as a sensor in cell cycle
checkpoint control. Knockdown of RFC4 contributes
to the decrease in intra-S phase checkpoints and
allowing more cells with DNA damage to enter the
S-phase where they are unable to combine with EdU
and subsequently fails to prevent cells with DNA
damage from entering mitosis. In addition, RFC4, to-
gether with PCNA, is required for large loop DNA
repair synthesis [20]. Other studies demonstrated that
RFC recruits DNA polymerase delta to sites of nu-
cleotide excision repair but is not required for the re-
cruitment of PCNA [21]. Regardless, the DNA damage
checkpoint is critical for repair in response to DNA
damage caused by some chemotherapeutic agents.
Interestingly, a previous study revealed that the
downregulation of RFC4 can enhance the cytotoxic
effects of doxorubicin and camptothecin in hepatocellular
carcinoma cells [19]. Together, these findings indicate
that decreasing RFC4 may sensitize colon cancer cells
to DNA damaging agents that are commonly used in
chemotherapy.
Conclusion
In summary, our results reveal that the overexpression
of RFC4 commonly occurs in CRC, and that a high level
of RFC4 is associated with poorly differentiated and late
TNM stages in patients with CRC. Higher levels of
RFC4 protein expression correlate with a worsened
overall survival in CRC. Yet, we appreciate that these
findings need to be validated in independent sets of
clinical samples in future study. The underlying
mechanism appears to involve RFC4, which promotes
cancer cell proliferation, while reducing the RFC4
levels induces the formation of an enriched population of
CRC cells in the S phase and a decrease in CRC cells
proliferation.Additional file
Additional file 1: Screenshot of the profile of the human RFC4 gene
within the BioGPS online portal. All data used for this study are
available through the BioGPS database (Biogps.org). Gene expression
profile is displayed as a bar chart.
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